Lyons Rimmer, J.; Ercolano, E.; Baiz, D.; Makhija, M.; Berger, A.; Sells, T.; Stroud, S.; Hilton, D.; Adams, C.L.; Hanemann, C.O.
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. Cancers 2020, 12, 1744.
https://doi.org/10.3390/cancers12071744
AMA Style
Lyons Rimmer J, Ercolano E, Baiz D, Makhija M, Berger A, Sells T, Stroud S, Hilton D, Adams CL, Hanemann CO.
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. Cancers. 2020; 12(7):1744.
https://doi.org/10.3390/cancers12071744
Chicago/Turabian Style
Lyons Rimmer, Jade, Emanuela Ercolano, Daniele Baiz, Mahindra Makhija, Allison Berger, Todd Sells, Steve Stroud, David Hilton, Claire L. Adams, and C Oliver Hanemann.
2020. "The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma" Cancers 12, no. 7: 1744.
https://doi.org/10.3390/cancers12071744
APA Style
Lyons Rimmer, J., Ercolano, E., Baiz, D., Makhija, M., Berger, A., Sells, T., Stroud, S., Hilton, D., Adams, C. L., & Hanemann, C. O.
(2020). The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. Cancers, 12(7), 1744.
https://doi.org/10.3390/cancers12071744